[Burkitt's lymphoma in relation to acquired immunodeficiency syndrome (AIDS)]

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

ESMO open·2024

Visual and semi-quantitative analysis of 6-[18F]FDOPA PET/CT in patients with brain tumors and suspected tumor recurrence versus radionecrosis.

Revista espanola de medicina nuclear e imagen molecular·2023

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

BMC cancer·2019

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Joint pain: a practical guide to the diagnosis of arthritis.

Revista clinica espanola·2026

Stickler syndrome type 1: case series and new genetic variants.

Revista clinica espanola·2026

Executive summary of the consensus document for recommendations on the treatment of venous thromboembolism in pregnancy: Consensus document from the Spanish Society of Internal Medicine, the Spanish Society of Medical Radiology, the Spanish Society of Vascular Interventional Radiology and the Spanish Society of Gynecology and Obstetrics 2026.

Revista clinica espanola·2026

Treatment of osteoporosis in clinical practice: when, whom, how, and for how long.

Revista clinica espanola·2026

Metabolic alkalosis and clinical outcomes in acute heart failure: a systematic review and meta-analysis.

Revista clinica espanola·2026

Pulmonary embolism: what does the new AHA/ACC 2026 guide add.

Revista clinica espanola·2026

Allopurinol-Induced Leukocytoclastic Vasculitis With Systemic Inflammatory Response: A Case Report From Azerbaijan.

Cureus·2026

From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.

Frontiers in immunology·2026

TREM2 as a central hub of neuroimmune-metabolic crosstalk in central nervous system disorders: from microglial biology to therapeutic targeting.

Frontiers in immunology·2026

The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics.

Frontiers in immunology·2026

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities.

MedComm·2026

Molecular basis of post-translational neoantigen generation in rheumatoid arthritis: breaking immunological tolerance and implications for targeted therapy.

Frontiers in immunology·2026

Related Experiment Videos

[Burkitt's lymphoma in relation to acquired immunodeficiency syndrome (AIDS)]

Related Concept Videos

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

Visual and semi-quantitative analysis of 6-[18F]FDOPA PET/CT in patients with brain tumors and suspected tumor recurrence versus radionecrosis.

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Joint pain: a practical guide to the diagnosis of arthritis.

Stickler syndrome type 1: case series and new genetic variants.

Treatment of osteoporosis in clinical practice: when, whom, how, and for how long.

Metabolic alkalosis and clinical outcomes in acute heart failure: a systematic review and meta-analysis.

Pulmonary embolism: what does the new AHA/ACC 2026 guide add.

Allopurinol-Induced Leukocytoclastic Vasculitis With Systemic Inflammatory Response: A Case Report From Azerbaijan.

From inflammation to rupture: advances in the pathogenesis of pseudoaneurysm formation in Vascular Behçet's Disease.

TREM2 as a central hub of neuroimmune-metabolic crosstalk in central nervous system disorders: from microglial biology to therapeutic targeting.

The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics.

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities.

Molecular basis of post-translational neoantigen generation in rheumatoid arthritis: breaking immunological tolerance and implications for targeted therapy.

Related Experiment Videos

[Burkitt's lymphoma in relation to acquired immunodeficiency syndrome (AIDS)]

Related Concept Videos

Related Articles